These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1156021)

  • 1. Tolerance development to the effect of delta9-tetrahydrocannabinol on conditioned behavior: role of treatment interval and influence of microsomal metabolism.
    Davis WM; Borgen LA
    Arch Int Pharmacodyn Ther; 1975 Jan; 213(1):97-112. PubMed ID: 1156021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delta9-tetrahydrocannabinol and 11-hydroxy-delta9-tetrahydrocannabinol: behavioral effects and tolerance development.
    Kosersky DS; McMillan DE; Harris LS
    J Pharmacol Exp Ther; 1974 Apr; 189(1):61-5. PubMed ID: 4823300
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition of arylhydrocarbon hydroxylase induction in BALB/C mouse liver by delta9-tetrahydrocannabinol.
    Friedman MA
    Res Commun Chem Pathol Pharmacol; 1976 Nov; 15(3):541-52. PubMed ID: 996365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of delta9-tetrahydrocannabinol and cannabinol on operant performance in rats.
    Karniol IG; Takahashi RN; Musty RE
    Arch Int Pharmacodyn Ther; 1974 Dec; 212(2):230-7. PubMed ID: 4447406
    [No Abstract]   [Full Text] [Related]  

  • 5. Tolerance to the reinforcing effects of morphine in delta9-tetrahydrocannabinol treated mice.
    Jardinaud F; Roques BP; Noble F
    Behav Brain Res; 2006 Oct; 173(2):255-61. PubMed ID: 16884789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. delta9-Tetrahydrocannabinol: tolerance after noncontingent exposure in rats.
    Järbe TU
    Arch Int Pharmacodyn Ther; 1978 Jan; 231(1):49-56. PubMed ID: 637625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasoconstrictor actions of delta8- and delta9-tetrahydrocannabinol in the rat.
    Adams MD; Earnhardt JT; Dewey WL; Harris LS
    J Pharmacol Exp Ther; 1976 Mar; 196(3):649-56. PubMed ID: 4606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive effects of delta9-tetrahydrocannabinol.
    Kosersky DS
    Arch Int Pharmacodyn Ther; 1978 May; 233(1):76-81. PubMed ID: 686909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-retained metabolites of delta9- and delta8-tetrahydrocannabinols identified as novel fatty acid conjugates.
    Leighty EG; Fentiman AF; Foltz RL
    Res Commun Chem Pathol Pharmacol; 1976 May; 14(1):13-28. PubMed ID: 935647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of delta9-tetrahydrocannabinol and cannabidiol on the metabolism of gonadal steroids in the rat.
    List A; Nazar B; Nyquist S; Harclerode J
    Drug Metab Dispos; 1977; 5(3):268-72. PubMed ID: 17525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute and subchronic influences of tetrahydrocannabinols on water and food intake, body weight, and temperature in rats.
    Johansson JO; Jarbe TU; Henriksson BG
    TIT J Life Sci; 1975; 5(1-2):17-27. PubMed ID: 1188935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin.
    Bland TM; Haining RL; Tracy TS; Callery PS
    Biochem Pharmacol; 2005 Oct; 70(7):1096-103. PubMed ID: 16112652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of the development of tolerance to an anticonvulsant effect of delta9-tetrahydrocannabinol and cannabidiol.
    Karler R; Cely W; Turkanis SA
    Res Commun Chem Pathol Pharmacol; 1974 Sep; 9(1):23-39. PubMed ID: 4438826
    [No Abstract]   [Full Text] [Related]  

  • 14. Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification.
    Cichewicz DL; Martin ZL; Smith FL; Welch SP
    J Pharmacol Exp Ther; 1999 May; 289(2):859-67. PubMed ID: 10215664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative pharmacology of Delta9-tetrahydrocannabinol and its metabolite, 11-OH-Delta9-tetrahydrocannabinol.
    Lemberger L; Martz R; Rodda B; Forney R; Rowe H
    J Clin Invest; 1973 Oct; 52(10):2411-7. PubMed ID: 4729039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time course of the enhancement and restoration of the analgesic efficacy of codeine and morphine by delta9-tetrahydrocannabinol.
    Williams IJ; Edwards S; Rubo A; Haller VL; Stevens DL; Welch SP
    Eur J Pharmacol; 2006 Jun; 539(1-2):57-63. PubMed ID: 16687136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of repeated administration of delta9-tetrahydrocannabinol on serotonin metabolism in the rat brain.
    Sofia RD; Dixit BN; Barry H
    Arch Int Pharmacodyn Ther; 1977 Sep; 229(1):52-8. PubMed ID: 931467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of chronic administration of delta9-tetrahydrocannabinol on the heart rate of mongrel dogs.
    Jandhyala BS; Malloy KP; Buckley JP
    Res Commun Chem Pathol Pharmacol; 1976 May; 14(1):201-4. PubMed ID: 935652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delta9-tetrahydrocannabinol and some CNS depressants: evidence for cross-tolerance in the rat.
    Newman LM; Lutz MP; Domino EF
    Arch Int Pharmacodyn Ther; 1974 Feb; 207(2):254-9. PubMed ID: 4827412
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative diuretic activity of delta9-tetrahydrocannabinol, cannabidiol, cannabinol and hydrochlorothiazide in the rat.
    Sofia RD; Knobloch LC; Harakal JJ; Erikson DJ
    Arch Int Pharmacodyn Ther; 1977 Jan; 225(1):77-87. PubMed ID: 849066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.